FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Thomas Griffith

Research Profile

Chemicals & Drugs

Living Beings

Physiology

Immune Tolerance

Anatomy

Procedures

Genetic Therapy

Co-author Network

Publications

TOP 3
Stephanie A Condotta; Thomas Griffith; Britnie R James; Deepa Rai; Vladimir P Badovinac
Sustained and incomplete recovery of naive CD8+ T cell precursors after sepsis contributes to impaired CD8+ T cell responses to infection.
Ahter D Sanlioglu; Mustafa Kemal Balci; Thomas Griffith; Bahri Karacay; Salih Sanlioglu
Therapeutic potential of VIP vs PACAP in diabetes.
Britnie R James; Tamara Kucaba; Eric J Askeland; Thomas Griffith; Ann Tomanek-Chalkley; Lyse A Norian
Diet-induced obesity alters dendritic cell function in the presence and absence of tumor growth.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Thomas Griffith (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Stephanie A Condotta; Thomas Griffith; Britnie R James; Deepa Rai; Vladimir P Badovinac
Sustained and incomplete recovery of naive CD8+ T cell precursors after sepsis contributes to impaired CD8+ T cell responses to infection.
Journal of immunology (Baltimore, Md. : 1950) 2013;190(5):1991-2000.
2012: Ahter D Sanlioglu; Mustafa Kemal Balci; Thomas Griffith; Bahri Karacay; Salih Sanlioglu
Therapeutic potential of VIP vs PACAP in diabetes.
Journal of molecular endocrinology 2012;49(3):R157-67.
2012: Britnie R James; Tamara Kucaba; Eric J Askeland; Thomas Griffith; Ann Tomanek-Chalkley; Lyse A Norian
Diet-induced obesity alters dendritic cell function in the presence and absence of tumor growth.
Journal of immunology (Baltimore, Md. : 1950) 2012;189(3):1311-21.
2012: Henry M Rosevear; Aliasger K Salem; Carlos A Ariza; Barry R De Young; Thomas Griffith; Yogita Krishnamachari; Surya Mallapragada; Moshe Wald
Effect of combined locally delivered growth factors and systemic sildenafil citrate on microrecanalization in biodegradable conduit for vas deferens reconstruction.
Urology 2012;79(4):967.e1-4.
2012: Ahter D Sanlioglu; Hasan Altunbas; Mustafa Kemal Balci; Thomas Griffith; Salih Sanlioglu
Insulin gene therapy from design to beta cell generation.
Expert reviews in molecular medicine 2012;14():e18.
2012: Lyse A Norian; Timothy R Rosean; Henry M Rosevear; Christopher Schwarz; Christine J Weydert; Michael Henry; Britnie R James; Timothy P Kresowik; Tamara Kucaba; Andrew J Lightfoot; Thomas Griffith
Eradication of metastatic renal cell carcinoma after adenovirus-encoded TNF-related apoptosis-inducing ligand (TRAIL)/CpG immunotherapy.
PloS one 2012;7(2):e31085.
2011: Erik L Brincks; Prajwal Gurung; Emily A Hemann; Ryan A Langlois; Kevin Legge; Thomas Griffith
The magnitude of the T cell response to a clinically significant dose of influenza virus is regulated by TRAIL.
Journal of immunology (Baltimore, Md. : 1950) 2011;187(9):4581-8.
2011: Burcak Yoldas; Salih Sanlioglu; Tuba Canpolat; Isilay Dogan; Thomas Griffith; Ozlem Ozen; Cem Ozer; Levent N Ozluoglu
Clinical significance of TRAIL and TRAIL receptors in patients with head and neck cancer.
Head & neck 2011;33(9):1278-84.
2011: Prajwal Gurung; Deepa Rai; Jeffrey C Babcock; Vladimir P Badovinac; Stephanie A Condotta; Thomas Griffith
Immune unresponsiveness to secondary heterologous bacterial infection after sepsis induction is TRAIL dependent.
Journal of immunology (Baltimore, Md. : 1950) 2011;187(5):2148-54.
2011: Sevim Kahraman; Saffet Ozturk; Salih Sanlioglu; Ercument Dirice; Mustafa G Ertosun; Thomas Griffith; Fatma Z Hapil; Ahter D Sanlioglu
Tracing of islet graft survival by way of in vivo fluorescence imaging.
Diabetes/metabolism research and reviews 2011;27(6):575-83.
2011: Thomas Griffith; Erik L Brincks; Prajwal Gurung; Tamara Kucaba; Thomas A Ferguson
Systemic immunological tolerance to ocular antigens is mediated by TRAIL-expressing CD8+ T cells.
Journal of immunology (Baltimore, Md. : 1950) 2011;186(2):791-8.
2011: Thomas Griffith; Tamara Kucaba; Michael A O'Donnell; Jennifer Burns; Christopher Benetatos; Mark A McKinlay; Stephen Condon; Srinivas Chunduru
Sensitization of human bladder tumor cells to TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis with a small molecule IAP antagonist.
Apoptosis : an international journal on programmed cell death 2011;16(1):13-26.
2010: Prajwal Gurung; Tamara A Kucaba; Stephen P Schoenberger; Thomas A Ferguson; Thomas Griffith
TRAIL-expressing CD8+ T cells mediate tolerance following soluble peptide-induced peripheral T cell deletion.
Journal of leukocyte biology 2010;88(6):1217-25.
2010: Peter A Holoch; Surya Mallapragada; Carlos A Ariza; Thomas Griffith; Barry R DeYoung; Moshe Wald
Micro-recanalization in a biodegradable graft for reconstruction of the vas deferens is enhanced by sildenafil citrate.
Asian journal of andrology 2010;12(6):814-8.
2010: Henry M Rosevear; Andrew J Lightfoot; Thomas Griffith
Conatumumab, a fully human mAb against death receptor 5 for the treatment of cancer.
Current opinion in investigational drugs (London, England : 2000) 2010;11(6):688-98.
2010: Cigdem Aydin; Ahter D Sanlioglu; ATIL BISGIN; Burcak Yoldas; Levent Dertsiz; Bahri Karacay; Thomas Griffith; Salih Sanlioglu
NF-κB targeting by way of IKK inhibition sensitizes lung cancer cells to adenovirus delivery of TRAIL.
BMC cancer 2010;10():584.
2009: Peter A Holoch; Thomas Griffith
TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies.
European journal of pharmacology 2009;625(1-3):63-72.
2009: Henry M Rosevear; Andrew J Lightfoot; Michael A O'Donnell; Thomas Griffith
The role of neutrophils and TNF-related apoptosis-inducing ligand (TRAIL) in bacillus Calmette-Guérin (BCG) immunotherapy for urothelial carcinoma of the bladder.
Cancer metastasis reviews 2009;28(3-4):345-53.
2009: Prajwal Gurung; Tamara A Kucaba; Thomas A Ferguson; Thomas Griffith
Activation-induced CD154 expression abrogates tolerance induced by apoptotic cells.
Journal of immunology (Baltimore, Md. : 1950) 2009;183(10):6114-23.
2009: Ercument Dirice; Ahter D Sanlioglu; Sevim Kahraman; Saffet Ozturk; Mustafa Kemal Balci; Abdulkadir Omer; Thomas Griffith; Salih Sanlioglu
Adenovirus-mediated TRAIL gene (Ad5hTRAIL) delivery into pancreatic islets prolongs normoglycemia in streptozotocin-induced diabetic rats.
Human gene therapy 2009;20(10):1177-89.
2009: Christopher M Simons; Barry R De Young; Thomas Griffith; Timothy L Ratliff; Erin Jones; Surya Mallapragada; Moshe Wald
Early microrecanalization of vas deferens following biodegradable graft implantation in bilaterally vasectomized rats.
Asian journal of andrology 2009;11(3):373-8.
2009: Timothy P Kresowik; Thomas Griffith
Bacillus Calmette-Guerin immunotherapy for urothelial carcinoma of the bladder.
Immunotherapy 2009;1(2):281-8.
2009: Ahter D Sanlioglu; Ercument Dirice; Ozlem Elpek; Aylin F Korcum; Mustafa Ozdogan; I Suleymanlar; Mustafa Kemal Balci; Thomas Griffith; Salih Sanlioglu
High TRAIL death receptor 4 and decoy receptor 2 expression correlates with significant cell death in pancreatic ductal adenocarcinoma patients.
Pancreas 2009;38(2):154-60.
2009: Thomas Griffith; Brittany Stokes; Tamara Kucaba; James K Earel; Rebecca L Vanoosten; Erik L Brincks; Lyse A Norian
TRAIL gene therapy: from preclinical development to clinical application.
Current gene therapy 2009;9(1):9-19.
2009: Thomas Griffith
Induction of tumor cell apoptosis by TRAIL gene therapy.
Methods in molecular biology (Clifton, N.J.) 2009;542():315-34.
2008: Erik L Brincks; Tamara A Kucaba; Kevin Legge; Thomas Griffith
Influenza-induced expression of functional tumor necrosis factor-related apoptosis-inducing ligand on human peripheral blood mononuclear cells.
Human immunology 2008;69(10):634-46.
2008: Mark P Simons; Michael A O'Donnell; Thomas Griffith
Role of neutrophils in BCG immunotherapy for bladder cancer.
Urologic oncology 2008;26(4):341-5.
2008: Ahter D Sanlioglu; Thomas Griffith; Abdulkadir Omer; Ercument Dirice; Ramazan Sari; Hasan Altunbas; Mustafa Kemal Balci; Salih Sanlioglu
Molecular mechanisms of death ligand-mediated immune modulation: a gene therapy model to prolong islet survival in type 1 diabetes.
Journal of cellular biochemistry 2008;104(3):710-20.
2008: Ahter D Sanlioglu; Ercument Dirice; Ozlem Elpek; Aylin F Korcum; Mustafa Kemal Balci; Abdulkadir Omer; Thomas Griffith; Salih Sanlioglu
High levels of endogenous tumor necrosis factor-related apoptosis-inducing ligand expression correlate with increased cell death in human pancreas.
Pancreas 2008;36(4):385-93.
2008: Ismail Turker Koksal; Ahter D Sanlioglu; Bahri Karacay; Thomas Griffith; Salih Sanlioglu
Tumor necrosis factor-related apoptosis inducing ligand-R4 decoy receptor expression is correlated with high Gleason scores, prostate-specific antigen recurrence, and decreased survival in patients with prostate carcinoma.
Urologic oncology 2008;26(2):158-65.
2008: Mark P Simons; Kevin Leidal; William M Nauseef; Thomas Griffith
TNF-related apoptosis-inducing ligand (TRAIL) is expressed throughout myeloid development, resulting in a broad distribution among neutrophil granules.
Journal of leukocyte biology 2008;83(3):621-9.
2007: Rebecca L Vanoosten; Thomas Griffith
Activation of tumor-specific CD8+ T Cells after intratumoral Ad5-TRAIL/CpG oligodeoxynucleotide combination therapy.
Cancer research 2007;67(24):11980-90.
2007: Janet I Andrews; Thomas Griffith; Jeffery L Meier
Cytomegalovirus and the role of interferon in the expression of tumor necrosis factor-related apoptosis-inducing ligand in the placenta.
American journal of obstetrics and gynecology 2007;197(6):608.e1-6.
2007: Ahter D Sanlioglu; Bahri Karacay; Ismail Turker Koksal; Thomas Griffith; Salih Sanlioglu
DcR2 (TRAIL-R4) siRNA and adenovirus delivery of TRAIL (Ad5hTRAIL) break down in vitro tumorigenic potential of prostate carcinoma cells.
Cancer gene therapy 2007;14(12):976-84.
2007: Ahter D Sanlioglu; Aylin F Korcum; Elif Pestereli; Gülgün Erdogan; Seyda Karaveli; Burhan Savas; Thomas Griffith; Salih Sanlioglu
TRAIL death receptor-4 expression positively correlates with the tumor grade in breast cancer patients with invasive ductal carcinoma.
International journal of radiation oncology, biology, physics 2007;69(3):716-23.
2007: Thomas Griffith; Hirotaka Kazama; Rebecca L Vanoosten; James K Earle; John M Herndon; Douglas R Green; Thomas A Ferguson
Apoptotic cells induce tolerance by generating helpless CD8+ T cells that produce TRAIL.
Journal of immunology (Baltimore, Md. : 1950) 2007;178(5):2679-87.
2007: Rebecca L Vanoosten; James K Earel; Thomas Griffith
Histone deacetylase inhibitors enhance Ad5-TRAIL killing of TRAIL-resistant prostate tumor cells through increased caspase-2 activity.
Apoptosis : an international journal on programmed cell death 2007;12(3):561-71.
2007: Mark P Simons; Jill M Moore; Troy J Kemp; Thomas Griffith
Identification of the mycobacterial subcomponents involved in the release of tumor necrosis factor-related apoptosis-inducing ligand from human neutrophils.
Infection and immunity 2007;75(3):1265-71.
2007: Mark P Simons; William M Nauseef; Thomas Griffith
Neutrophils and TRAIL: insights into BCG immunotherapy for bladder cancer.
Immunologic research 2007;39(1-3):79-93.
2007: Thomas A Ferguson; Thomas Griffith
The role of Fas ligand and TNF-related apoptosis-inducing ligand (TRAIL) in the ocular immune response.
Chemical immunology and allergy 2007;92():140-54.
2006: Julieann F Grant; Toshihisa Iwasawa; Haley W Sinn; D Robert Siemens; Thomas Griffith; Elizabeth B Takacs; Timothy L Ratliff
Induction of protective immunity to RM-1 prostate cancer cells with ALVAC-IL-2/IL-12/TNF-alpha combination therapy.
International journal of cancer. Journal international du cancer 2006;119(11):2632-41.
2006: Mark P Simons; William M Nauseef; Thomas Griffith; Michael A Apicella
Neisseria gonorrhoeae delays the onset of apoptosis in polymorphonuclear leukocytes.
Cellular microbiology 2006;8(11):1780-90.
2006: Thomas A Ferguson; Thomas Griffith
A vision of cell death: Fas ligand and immune privilege 10 years later.
Immunological reviews 2006;213():228-38.
2006: Takeo Azuhata; David L Scott; Thomas Griffith; Michal Miller; Anthony D Sandler
Survivin inhibits apoptosis induced by TRAIL, and the ratio between survivin and TRAIL receptors is predictive of recurrent disease in neuroblastoma.
Journal of pediatric surgery 2006;41(8):1431-40.
2006: Vladimir P Badovinac; Kelly A N Messingham; Thomas Griffith; John T Harty
TRAIL deficiency delays, but does not prevent, erosion in the quality of "helpless" memory CD8 T cells.
Journal of immunology (Baltimore, Md. : 1950) 2006;177(2):999-1006.
2006: Rebecca L Vanoosten; James K Earel; Thomas Griffith
Enhancement of Ad5-TRAIL cytotoxicity against renal cell carcinoma with histone deacetylase inhibitors.
Cancer gene therapy 2006;13(6):628-32.
2006: James K Earel; Rebecca L Vanoosten; Thomas Griffith
Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cells.
Cancer research 2006;66(1):499-507.
2005: Troy J Kemp; Aaron T Ludwig; James K Earel; Jill M Moore; Rebecca L Vanoosten; Bonita Moses; Kevin Leidal; William M Nauseef; Thomas Griffith
Neutrophil stimulation with Mycobacterium bovis bacillus Calmette-Guerin (BCG) results in the release of functional soluble TRAIL/Apo-2L.
Blood 2005;106(10):3474-82.
2005: Rebecca L Vanoosten; Jill M Moore; Bahri Karacay; Thomas Griffith
Histone deacetylase inhibitors modulate renal cell carcinoma sensitivity to TRAIL/Apo-2L-induced apoptosis by enhancing TRAIL-R2 expression.
Cancer biology & therapy 2005;4(10):1104-12.
2005: Rebecca L Vanoosten; Jill M Moore; Aaron T Ludwig; Thomas Griffith
Depsipeptide (FR901228) enhances the cytotoxic activity of TRAIL by redistributing TRAIL receptor to membrane lipid rafts.
Molecular therapy : the journal of the American Society of Gene Therapy 2005;11(4):542-52.
2005: edith janssen; Nathalie M Droin; Edward E Lemmens; Michael J Pinkoski; Steven J Bensinger; Benjamin D Ehst; Thomas Griffith; Douglas R Green; Stephen P Schoenberger
CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death.
Nature 2005;434(7029):88-93.
2005: Bernd Jahrsdörfer; James E Wooldridge; Sue E Blackwell; Christiana M Taylor; Thomas Griffith; Brian K Link; George J Weiner
Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells.
Journal of leukocyte biology 2005;77(3):378-87.
2004: Scott A Crist; Bennett D Elzey; Aaron T Ludwig; Thomas Griffith; Jeffrey B Staack; Steven R Lentz; Timothy L Ratliff
Expression of TNF-related apoptosis-inducing ligand (TRAIL) in megakaryocytes and platelets.
Experimental hematology 2004;32(11):1073-81.
2004: Bahri Karacay; Salih Sanlioglu; Thomas Griffith; Anthony Sandler; Daniel J Bonthius
Inhibition of the NF-kappaB pathway enhances TRAIL-mediated apoptosis in neuroblastoma cells.
Cancer gene therapy 2004;11(10):681-90.
2004: Troy J Kemp; Jill M Moore; Thomas Griffith
Human B cells express functional TRAIL/Apo-2 ligand after CpG-containing oligodeoxynucleotide stimulation.
Journal of immunology (Baltimore, Md. : 1950) 2004;173(2):892-9.
2004: Aaron T Ludwig; Jill M Moore; Yi Luo; Xiaohong Chen; Nicole A Saltsgaver; Michael A O'Donnell; Thomas Griffith
Tumor necrosis factor-related apoptosis-inducing ligand: a novel mechanism for Bacillus Calmette-Guérin-induced antitumor activity.
Cancer research 2004;64(10):3386-90.
2003: Troy J Kemp; J-S Kim; Scott A Crist; Thomas Griffith
Induction of necrotic tumor cell death by TRAIL/Apo-2L.
Apoptosis : an international journal on programmed cell death 2003;8(6):587-99.
2003: Scott A Crist; Thomas Griffith; Timothy L Ratliff
Structure/function analysis of the murine CD95L promoter reveals the identification of a novel transcriptional repressor and functional CD28 response element.
The Journal of biological chemistry 2003;278(38):35950-8.
2003: Thomas Griffith; Troy J Kemp
The topoisomerase I inhibitor topotecan increases the sensitivity of prostate tumor cells to TRAIL/Apo-2L-induced apoptosis.
Cancer chemotherapy and pharmacology 2003;52(3):175-84.
2003: Troy J Kemp; Bennett D Elzey; Thomas Griffith
Plasmacytoid dendritic cell-derived IFN-alpha induces TNF-related apoptosis-inducing ligand/Apo-2L-mediated antitumor activity by human monocytes following CpG oligodeoxynucleotide stimulation.
Journal of immunology (Baltimore, Md. : 1950) 2003;171(1):212-8.
2003: Thomas A Ferguson; Patrick M Stuart; John M Herndon; Thomas Griffith
Apoptosis, tolerance, and regulatory T cells--old wine, new wineskins.
Immunological reviews 2003;193():111-23.
2002: Hae-ock Lee; John M Herndon; Ramon Barreiro; Thomas Griffith; Thomas A Ferguson
TRAIL: a mechanism of tumor surveillance in an immune privileged site.
Journal of immunology (Baltimore, Md. : 1950) 2002;169(9):4739-44.
2002: Thomas Griffith; Jonathan M Fialkov; David L Scott; Takeo Azuhata; Richard D Williams; Nathan Wall; Dario C Altieri; Anthony D Sandler
Induction and regulation of tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand-mediated apoptosis in renal cell carcinoma.
Cancer research 2002;62(11):3093-9.
2002: Thomas A Ferguson; John Herndon; Bennett D Elzey; Thomas Griffith; Stephen P Schoenberger; Douglas R Green
Uptake of apoptotic antigen-coupled cells by lymphoid dendritic cells and cross-priming of CD8(+) T cells produce active immune unresponsiveness.
Journal of immunology (Baltimore, Md. : 1950) 2002;168(11):5589-95.
2002: Thomas A Ferguson; Douglas R Green; Thomas Griffith
Cell death and immune privilege.
International reviews of immunology 2002;21(2-3):153-72.
2001: Bennett D Elzey; Thomas Griffith; John M Herndon; Ramon Barreiro; J Tschopp; Thomas A Ferguson
Regulation of Fas ligand-induced apoptosis by TNF.
Journal of immunology (Baltimore, Md. : 1950) 2001;167(6):3049-56.
2001: Thomas Griffith; E L Broghammer
Suppression of tumor growth following intralesional therapy with TRAIL recombinant adenovirus.
Molecular therapy : the journal of the American Society of Gene Therapy 2001;4(3):257-66.
2000: Thomas Griffith; Richard D Anderson; Beverly L Davidson; Richard D Williams; Timothy L Ratliff
Adenoviral-mediated transfer of the TNF-related apoptosis-inducing ligand/Apo-2 ligand gene induces tumor cell apoptosis.
Journal of immunology (Baltimore, Md. : 1950) 2000;165(5):2886-94.
1999: NA Fanger; Charles R Maliszewski; K Schooley; Thomas Griffith
Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).
The Journal of experimental medicine 1999;190(8):1155-64.
1999: Alicia Algeciras-Schimnich; Thomas Griffith; David H Lynch; Carlos V Paya
Cell cycle-dependent regulation of FLIP levels and susceptibility to Fas-mediated apoptosis.
Journal of immunology (Baltimore, Md. : 1950) 1999;162(9):5205-11.
1999: Thomas Griffith; S R Wiley; Marek Kubin; Lisa M Sedger; Charles R Maliszewski; NA Fanger
Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL.
The Journal of experimental medicine 1999;189(8):1343-54.
1999: Thomas Griffith; Charles T Rauch; Pam Smolak; JY Waugh; Norman Boiani; David H Lynch; CA Smith; RG Goodwin; Marek Kubin
Functional analysis of TRAIL receptors using monoclonal antibodies.
Journal of immunology (Baltimore, Md. : 1950) 1999;162(5):2597-605.
1999: Henning Walczak; R E Miller; K Ariail; Brian Gliniak; Thomas Griffith; Marek Kubin; W Chin; J Jones; A Woodward; Tiep Le; C Smith; Pam Smolak; RG Goodwin; Charles T Rauch; JoAnn C L Schuh; David H Lynch
Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.
Nature medicine 1999;5(2):157-63.
1998: E Bonfoco; Patrick M Stuart; Thomas Brunner; Tesu Lin; Thomas Griffith; Y Gao; H Nakajima; P A Henkart; Thomas A Ferguson; Douglas R Green
Inducible nonlymphoid expression of Fas ligand is responsible for superantigen-induced peripheral deletion of T cells.
Immunity 1998;9(5):711-20.
1998: Thomas Griffith; David H Lynch
TRAIL: a molecule with multiple receptors and control mechanisms.
Current opinion in immunology 1998;10(5):559-63.
1998: Thomas Griffith; W A Chin; G C Jackson; David H Lynch; Marek Kubin
Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells.
Journal of immunology (Baltimore, Md. : 1950) 1998;161(6):2833-40.
1998: Y Gao; John M Herndon; H Zhang; Thomas Griffith; Thomas A Ferguson
Antiinflammatory effects of CD95 ligand (FasL)-induced apoptosis.
The Journal of experimental medicine 1998;188(5):887-96.
1997: Thomas A Ferguson; Thomas Griffith
A vision of cell death: insights into immune privilege.
Immunological reviews 1997;156():167-84.
1997: Patrick M Stuart; Thomas Griffith; N Usui; Jay Pepose; X Yu; Thomas A Ferguson
CD95 ligand (FasL)-induced apoptosis is necessary for corneal allograft survival.
The Journal of clinical investigation 1997;99(3):396-402.
1997: Thomas A Ferguson; Thomas Griffith
Cell death and the immune response: a lesson from the privileged.
Journal of clinical immunology 1997;17(1):1-10.
1996: Thomas Brunner; N J Yoo; Thomas Griffith; Thomas A Ferguson; Douglas R Green
Regulation of CD95 ligand expression: a key element in immune regulation?
Behring Institute Mitteilungen 1996;(97):161-74.
1996: Thomas Griffith; X Yu; J M Herndon; Douglas R Green; Thomas A Ferguson
CD95-induced apoptosis of lymphocytes in an immune privileged site induces immunological tolerance.
Immunity 1996;5(1):7-16.
1995: Thomas Griffith; T Brunner; S M Fletcher; Douglas R Green; Thomas A Ferguson
Fas ligand-induced apoptosis as a mechanism of immune privilege.
Science (New York, N.Y.) 1995;270(5239):1189-92.
1995: Thomas Griffith; J M Herndon; J Lima; M Kahn; Thomas A Ferguson
The immune response and the eye. TCR alpha-chain related molecules regulate the systemic immunity to antigen presented in the eye.
International immunology 1995;7(10):1617-25.
1995: Thomas A Ferguson; S Fletcher; J Herndon; Thomas Griffith
Neuropeptides modulate immune deviation induced via the anterior chamber of the eye.
Journal of immunology (Baltimore, Md. : 1950) 1995;155(4):1746-56.
1994: Thomas A Ferguson; P Dube; Thomas Griffith
Regulation of contact hypersensitivity by interleukin 10.
The Journal of experimental medicine 1994;179(5):1597-604.